User:Mr. Ibrahem/Revefenacin

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Revefenacin
Clinical data
Trade namesYupelri
AHFS/Drugs.comMonograph
MedlinePlusa619009
Routes of
administration		Inhalation
Drug classLong-acting muscarinic antagonist (LAMA)[1]
Legal status
Legal status
Chemical and physical data
FormulaC35H43N5O4
Molar mass597.760 g·mol−1
3D model (JSmol)
  • CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N
  • InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43)
  • Key:FYDWDCIFZSGNBU-UHFFFAOYSA-N

Revefenacin, sold under the brand name Yupelri, is a medication used for the long term treat of chronic obstructive pulmonary disease (COPD).[1] It is used by breathing it into the lungs.[1]

Common side effects include cough, upper respiratory tract infection, headache, and back pain.[2] Other side effects may include allergic reactions, bronchospasm, and urinary retention.[1] It is a long-acting muscarinic antagonist (LAMA).[1]

Revefenacin was approved for medical use in the United States in 2018.[1] It is not available in the United Kingdom or Europe as of 2021.[3] In the United States it costs about 1,100 USD per month.[4]

References[edit]

  1. ^ a b c d e f g "Revefenacin Monograph for Professionals". Drugs.com. Archived from the original on 17 April 2021. Retrieved 16 October 2021.
  2. ^ a b c "DailyMed - YUPELRI- revefenacin solution". dailymed.nlm.nih.gov. Archived from the original on 4 August 2020. Retrieved 17 October 2021.
  3. ^ "Revefenacin". SPS - Specialist Pharmacy Service. 28 December 2015. Archived from the original on 17 October 2021. Retrieved 17 October 2021.
  4. ^ "Yupelri Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 17 October 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Revefenacin&oldid=1178481353"